Clinical application of adaptive immune therapy in MSS colorectal cancer patients
D Wang, H Zhang, T Xiang, G Wang - Frontiers in immunology, 2021 - frontiersin.org
Colorectal cancer (CRC) is one of the most common cancers worldwide. However, the
treatment outcomes of immunotherapy in microsatellite-stable (MSS) CRC remain …
treatment outcomes of immunotherapy in microsatellite-stable (MSS) CRC remain …
Cytokine therapy combined with nanomaterials participates in cancer immunotherapy
H Lian, S Ma, D Zhao, W Zhao, Y Cui, Y Hua, Z Zhang - Pharmaceutics, 2022 - mdpi.com
Immunotherapy has gradually become an emerging treatment modality for tumors after
surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for …
surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for …
A polygenic stacking classifier revealed the complicated platelet transcriptomic landscape of adult immune thrombocytopenia
C Xu, R Zhang, M Duan, Y Zhou, J Bao, H Lu… - … Therapy-Nucleic Acids, 2022 - cell.com
Immune thrombocytopenia (ITP) is an autoimmune disease with the typical symptom of a low
platelet count in blood. ITP demonstrated age and sex biases in both occurrences and …
platelet count in blood. ITP demonstrated age and sex biases in both occurrences and …
[PDF][PDF] On the Treatment of Pancreatic Ductal Adenocarcinoma–Arming Oncolytic Vesicular Stomatitis Virus with LIGHT
S Mansouri - 2024 - savoirs.usherbrooke.ca
Summary Pancreatic Ductal Adenocarcinoma (PDAC) will become North America's second
leading cancer killer by 2030. With a 5-year overall survival rate of 11%, insufficient …
leading cancer killer by 2030. With a 5-year overall survival rate of 11%, insufficient …